Jacobio Pharmaceuticals out‑licensed its clinical‑stage pan‑KRAS inhibitor JAB‑23E73 to AstraZeneca in a deal worth up to $1.915 billion, with AstraZeneca taking development and commercialization rights outside China. Jacobio will receive a $100 million upfront payment and is eligible for further milestones and royalties. AstraZeneca will lead global development efforts and share commercialization in China under a joint framework. AstraZeneca’s initial $100 million payment underscores its strategic push into KRAS‑directed oncology programs. The transaction accelerates global development for an oral pan‑KRAS candidate and signals continued big‑pharma appetite for early‑stage oncology assets from China.